Research LetterThe effect of Aliskiren on exercise capacity in older patients with heart failure and preserved ejection fraction: A randomized, placebo-controlled, double-blind trial
Section snippets
Limitations
The p-values for peak VO2 (0.10) and for VAT (0.08) suggest the study may have been underpowered, particularly for the effect size we observed which was less than our sample size estimate. We performed additional analyses which indicated that if the number of completed patients in the trial had been 119, and other results remained the same (such as effect size and variability), then the study would have been positive on peak VO2 at the 0.05 level of significance. Of course, that includes some
Acknowledgements / potential conflicts of interest
In addition to partial funding for the present study from Novartis (which had no role in study conduct, data analysis, interpretation, or manuscript generation), Dr. KItzman reports the following potential financial conflicts of interest: Consultant for Abbvie, Bayer, Merck, Medtronic, Relypsa, Merck, Corvia Medical, Boehringer-Ingelheim, GSK, and Actavis, current research grant funding from Novartis, Bayer, and GSK, and stock ownership in Gilead Sciences. Dr. Upadhya has received research
References (12)
- et al.
Prevalence and mortality rate of congestive heart failure in the United States
J Am Coll Cardiol
(1992) - et al.
Reliability of peak exercise testing in patients with heart failure with preserved ejection fraction
Am J Cardiol
(2012) - et al.
Renal protective effects of aliskiren beyond its antihypertensive property in a mouse model of progressive fibrosis
Am J Hypertens
(2011) - et al.
A randomized, controlled, double-blinded trial of enalapril in older patients with heart failure and preserved ejection fraction; effects on exercise tolerance, and arterial distensibility
Circ Heart Fail
(2010) - et al.
Effect of caloric restriction or aerobic exercise training on peak oxygen consumption and quality of life in obese older patients with heart failure with preserved ejection fraction: a randomised clinical trial
JAMA
(2016) - et al.
A multidisciplinary intervention to prevent the readmission of elderly patients with congestive heart failure
N Engl J Med
(1995)
Cited by (5)
Osteopontin Promotes Left Ventricular Diastolic Dysfunction Through a Mitochondrial Pathway
2019, Journal of the American College of CardiologyAngiotensin-Converting Enzyme and Hypertension: A Systemic Analysis of Various ACE Inhibitors, Their Side Effects, and Bioactive Peptides as a Putative Therapy for Hypertension
2023, JRAAS - Journal of the Renin-Angiotensin-Aldosterone SystemHypertension as a Road to Treatment of Heart Failure with Preserved Ejection Fraction
2020, Current Hypertension ReportsRenin activity in heart failure with reduced systolic function—new insights
2019, International Journal of Molecular Sciences
ClinicalTrials.gov Identifier: NCT00982033.
Funding Sources: This study was funded, in part, by an investigator-initiated grant from Novartis Pharmaceuticals. However, Novartis had no role in study conduct, data analysis, interpretation, or manuscript generation. Also funded in part by: NIH R01AG18915 and R01AG045551; The Claude D. Pepper Older Americans Independence Center of Wake Forest University NIH P30AG21332; Clinical and Translational Science Institute of Wake Forest School of Medicine NIH UL1TR001420; and the Kermit G. Phillips II Chair in Cardiovascular Medicine of Wake Forest School of Medicine.